$CCEL
CRYO CELL INTERNATIONAL INC

2020 Q1 Form 10-Q Financial Statement

#000119312520107163 Filed on April 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1 2018 Q4
Revenue $7.621M $7.495M $8.594M
YoY Change 1.68% 20.34% 32.82%
Cost Of Revenue $2.503M $2.466M $2.675M
YoY Change 1.5% 53.99% 63.1%
Gross Profit $5.118M $5.029M $5.919M
YoY Change 1.76% 8.69% 22.29%
Gross Profit Margin 67.15% 67.1% 68.87%
Selling, General & Admin $3.870M $3.745M $4.120M
YoY Change 3.33% 4.34% 16.37%
% of Gross Profit 75.62% 74.48% 69.6%
Research & Development $5.722K $5.884K $26.92K
YoY Change -2.75% -56.12% 34.6%
% of Gross Profit 0.11% 0.12% 0.45%
Depreciation & Amortization $95.76K $104.9K $103.1K
YoY Change -8.69% 74.78% 71.75%
% of Gross Profit 1.87% 2.09% 1.74%
Operating Expenses $3.876M $3.751M $4.202M
YoY Change 3.32% 4.11% 17.04%
Operating Profit $1.249M $853.7K $1.717M
YoY Change 46.32% -13.52% 37.36%
Interest Expense $365.3K $406.9K -$551.5K
YoY Change -10.23% 44.83% 49.04%
% of Operating Profit 29.25% 47.67% -32.12%
Other Income/Expense, Net -$309.7K -$473.1K -$39.24K
YoY Change -34.54% 50.41% 96.2%
Pretax Income $939.3K $380.5K $1.542M
YoY Change 146.84% -43.42% 79.26%
Income Tax $252.4K $104.7K $557.7K
% Of Pretax Income 26.87% 27.5% 36.18%
Net Earnings $687.0K $275.9K $890.8K
YoY Change 149.01% -110.9% 30.99%
Net Earnings / Revenue 9.01% 3.68% 10.37%
Basic Earnings Per Share $0.09 $0.04
Diluted Earnings Per Share $0.08 $0.03 $114.2K
COMMON SHARES
Basic Shares Outstanding 7.541M 7.801M 7.801M shares
Diluted Shares Outstanding 8.128M 8.425M

Balance Sheet

Concept 2020 Q1 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.375M $7.884M $6.916M
YoY Change 18.9% 4.01% 2.91%
Cash & Equivalents $8.416M $7.076M $6.040M
Short-Term Investments $959.0K $808.5K $875.7K
Other Short-Term Assets $199.1K $204.9K $254.5K
YoY Change -2.85% -4.17% 23.45%
Inventory $1.103M $16.13M $1.261M
Prepaid Expenses $451.7K $460.6K $461.8K
Receivables $5.767M $5.694M $5.867M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $16.89M $30.38M $14.76M
YoY Change -44.38% 126.83% 15.88%
LONG-TERM ASSETS
Property, Plant & Equipment $1.775M $1.465M $1.493M
YoY Change 21.17% 34.74% 69.25%
Goodwill $1.941M $1.941M $1.941M
YoY Change 0.0%
Intangibles $1.232M $1.314M $1.341M
YoY Change -6.25% 216.53% 492.42%
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0%
Other Assets $26.06M $11.50M $26.14M
YoY Change 126.59% 54.75% 153.99%
Total Long-Term Assets $27.84M $12.97M $28.13M
YoY Change 114.68% 52.2% 151.73%
TOTAL ASSETS
Total Short-Term Assets $16.89M $30.38M $14.76M
Total Long-Term Assets $27.84M $12.97M $28.13M
Total Assets $44.73M $43.34M $42.89M
YoY Change 3.2% 97.81% 79.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.381M $1.010M $1.262M
YoY Change 36.7% -15.65% -34.58%
Accrued Expenses $2.714M $2.902M $2.703M
YoY Change -6.47% 1.26% 4.66%
Deferred Revenue $8.610M $8.267M $8.365M
YoY Change 4.15%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.100M $3.100M
YoY Change 0.0% 55.0% 55.0%
Total Short-Term Liabilities $16.07M $15.28M $15.43M
YoY Change 5.18% 14.77% 10.69%
LONG-TERM LIABILITIES
Long-Term Debt $5.106M $1.425M $1.425M
YoY Change 258.29% 0.0% 0.0%
Other Long-Term Liabilities $34.66M $36.30M $35.87M
YoY Change -4.51% 58.13% 59.61%
Total Long-Term Liabilities $34.66M $37.72M $37.29M
YoY Change -8.12% 54.73% 56.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.07M $15.28M $15.43M
Total Long-Term Liabilities $34.66M $37.72M $37.29M
Total Liabilities $50.73M $51.58M $51.30M
YoY Change -1.64% 42.21% 40.88%
SHAREHOLDERS EQUITY
Retained Earnings -$21.76M -$24.46M -$25.33M
YoY Change -11.05% -9.43% 3.49%
Common Stock $36.32M $35.80M $35.65M
YoY Change 1.46% 11.65% 13.17%
Preferred Stock
YoY Change
Treasury Stock (at cost) $20.56M $19.57M $19.57M
YoY Change 5.07% 0.0% 0.0%
Treasury Stock Shares $6.094M 5.801M shares $5.801M
Shareholders Equity -$6.001M -$8.234M -$8.908M
YoY Change
Total Liabilities & Shareholders Equity $44.73M $43.34M $42.39M
YoY Change 3.2% 97.81% 77.29%

Cashflow Statement

Concept 2020 Q1 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income $687.0K $275.9K $890.8K
YoY Change 149.01% -110.9% 30.99%
Depreciation, Depletion And Amortization $95.76K $104.9K $103.1K
YoY Change -8.69% 74.78% 71.75%
Cash From Operating Activities $2.616M $1.854M $844.0K
YoY Change 41.07% 9.59% -60.0%
INVESTING ACTIVITIES
Capital Expenditures $6.961K $49.09K -$37.86K
YoY Change -85.82% -80.65% -5.35%
Acquisitions
YoY Change
Other Investing Activities -$31.06K
YoY Change -203.53%
Cash From Investing Activities -$6.961K -$49.09K -$68.93K
YoY Change -85.82% -89.81% 244.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -734.0K -769.3K -1.775M
YoY Change -4.59% 54.56% 269.79%
NET CHANGE
Cash From Operating Activities 2.616M 1.854M 844.0K
Cash From Investing Activities -6.961K -49.09K -68.93K
Cash From Financing Activities -734.0K -769.3K -1.775M
Net Change In Cash 1.875M 1.036M -999.9K
YoY Change 81.01% 45.41% -162.11%
FREE CASH FLOW
Cash From Operating Activities $2.616M $1.854M $844.0K
Capital Expenditures $6.961K $49.09K -$37.86K
Free Cash Flow $2.609M $1.805M $881.8K
YoY Change 44.52% 25.5% -58.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7620774
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7495112
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2503144
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2466227
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3870029
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3745302
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5722
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5884
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
44221
CY2019Q1 us-gaap Interest Expense
InterestExpense
406925
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-309724
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
56980
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
6371704
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
6641450
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
627
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
986
CY2020Q1 us-gaap Interest Expense
InterestExpense
365299
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-473118
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
939346
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
380544
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
252380
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
104667
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8128257
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8424905
CY2020Q1 us-gaap Profit Loss
ProfitLoss
686966
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
95757
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
104870
CY2020Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-51412
CY2019Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
367057
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
224258
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
138982
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
152991
CY2019Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
240643
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
24481
CY2019Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
29894
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-177656
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
67470
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-48588
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1261
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-70394
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
96712
CY2020Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-61333
CY2019Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-49570
CY2020Q1 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
18210
CY2019Q1 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-68250
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12131
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-251261
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
628627
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
217220
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
556760
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
708682
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2615563
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1854042
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6961
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
49085
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6961
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49085
CY2020Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
775000
CY2019Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
774999
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5700
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-734000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-769299
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1874602
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1035658
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6040033
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7075691
CY2019Q1 us-gaap Profit Loss
ProfitLoss
275877
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6952851
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
41000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
224258
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5700
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
138982
CY2019Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
253447
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-8234292
CY2020Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
416745
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
398535
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5766684
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6097331
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8610304
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8875138
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
24454967
CY2018Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
329231
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
109780
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
23633373
CY2020Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
33065271
CY2020Q1 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
8610304
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2018Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
66533
CY2020Q1 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
23320
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1249070
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
853662
CY2020Q1 us-gaap Interest Expense
InterestExpense
365299
CY2019Q1 us-gaap Interest Expense
InterestExpense
406925
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
252380
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
104667
CY2018Q4 us-gaap Assets
Assets
42886160
CY2020Q1 ccel Inventory Collection Kits
InventoryCollectionKits
51687
CY2019Q4 ccel Inventory Collection Kits
InventoryCollectionKits
44453
CY2020Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2020Q1 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13660139
CY2019Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13730533
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17000
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27000
CY2019Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
180244
CY2020Q1 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
24481
CY2019Q1 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
29894
CY2020Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
134261
CY2019Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
210138
CY2020Q1 us-gaap Notes Payable
NotesPayable
8333433
CY2019Q4 us-gaap Notes Payable
NotesPayable
9108433
CY2020Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
127800
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
152281
CY2020Q1 us-gaap Long Term Debt
LongTermDebt
8205633
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
8956152
CY2020Q1 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2020Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
5105633
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5856152
CY2020Q1 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2020Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6093535
CY2020Q1 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod
30000
CY2020Q1 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cash Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCashPayments
444000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
125234
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.70
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
44969
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 us-gaap Other Assets Current
OtherAssetsCurrent
199064
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.03
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
62083
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.51
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
108120
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.95
CY2020Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1114743
CY2020Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.49
CY2020Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1006623
CY2020Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y11M8D
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-02-29
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7545613
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8415639
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6541037
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
959001
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
904053
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
451672
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
500260
CY2020Q1 us-gaap Inventory Net
InventoryNet
1102824
CY2019Q4 us-gaap Inventory Net
InventoryNet
1084533
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
260397
CY2020Q1 us-gaap Assets Current
AssetsCurrent
16894884
CY2019Q4 us-gaap Assets Current
AssetsCurrent
15387611
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1774587
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1846467
CY2020Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1232338
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1249254
CY2020Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
12557315
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
12646000
CY2020Q1 us-gaap Goodwill
Goodwill
1941411
CY2019Q4 us-gaap Goodwill
Goodwill
1941411
CY2020Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9079994
CY2019Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9079994
CY2020Q1 ccel Deposits And Other Assets
DepositsAndOtherAssets
445633
CY2019Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
427423
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26060975
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25652082
CY2020Q1 us-gaap Assets
Assets
44730446
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Assets
Assets
42886160
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1381242
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1369111
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2713807
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2085180
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
16070151
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15429429
CY2020Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3443645
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3495057
CY2020Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2019Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34660922
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34409582
CY2020Q1 us-gaap Liabilities
Liabilities
50731073
CY2019Q4 us-gaap Liabilities
Liabilities
49839011
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
136336
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
135989
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36183738
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35918827
CY2020Q1 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
20563357
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21757344
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22444310
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-6000627
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44730446
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42886160
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2631883
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2584091
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13633638
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7545613
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13598909
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7510884
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2019Q1 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
-340984
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-8908298
CY2019Q1 us-gaap Cumulative Effect On Retained Earnings Tax1
CumulativeEffectOnRetainedEarningsTax1
94192
CY2020Q1 ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2019Q1 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
20954
CY2020Q1 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
11535
CY2019Q1 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
6643
CY2020Q1 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
224000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
139000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2019Q1 ccel Cumulative Effect Adjustment From Accumulated Other Comprehensive Income To Retained Earnings
CumulativeEffectAdjustmentFromAccumulatedOtherComprehensiveIncomeToRetainedEarnings
341000
CY2020Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
55000
CY2019Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
67000
CY2020Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1232338
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1249254
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
686966
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
275877
CY2020Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
587144
CY2019Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
623572
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7541113
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7801333
CY2020Q1 ccel Types Of License Agreements
TypesOfLicenseAgreements
2
CY2020Q1 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
CY2020Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2019Q1 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company’s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December 1, 2020 and the remaining 1/3 on November 30, 2021.
CY2020Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
3.06
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2020Q1 dei Trading Symbol
TradingSymbol
CCEL
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
496284
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
264798
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
231677
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
54948
CY2019Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-67179
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
54948
CY2019Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-67179
CY2020Q1 ccel Amortization Of Operating Lease Right Of Use Asset
AmortizationOfOperatingLeaseRightOfUseAsset
66491
CY2020Q1 ccel Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-66300
CY2020Q1 ccel Operating Leaseright Of Useasset Recorded Due To Adoption Of Asc842
OperatingLeaserightOfUseassetRecordedDueToAdoptionOfAsc842
562775
CY2020Q1 ccel Operating Lease Liability Recorded Due To Adoption Of Asc842
OperatingLeaseLiabilityRecordedDueToAdoptionOfAsc842
562775
CY2020Q1 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; background: none;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Warranty and Cryo-Cell Cares<div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;vertical-align: super;font-size: smaller;display:inline;">TM</div> Program </div></div></div><div style="text-indent: 4%;font-family: &quot;times new roman&quot;;font-size: 10pt;margin-top: 6pt;margin-bottom: 0pt;background: none;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#160;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June&#160;1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, </div> <div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background: none; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">PrepaCyte CB</div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;">. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. </div></div><div style="text-indent: 4%;font-family: &quot;times new roman&quot;;font-size: 10pt;margin-top: 12pt;margin-bottom: 0pt;background: none;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits at February&#160;29, 2020.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
496475
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
213635
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
284846
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
23737
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25743
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
66300
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NONE

Files In Submission

Name View Source Status
0001193125-20-107163-index-headers.html Edgar Link pending
0001193125-20-107163-index.html Edgar Link pending
0001193125-20-107163.txt Edgar Link pending
0001193125-20-107163-xbrl.zip Edgar Link pending
ccel-20200229.xml Edgar Link completed
ccel-20200229.xsd Edgar Link pending
ccel-20200229_cal.xml Edgar Link unprocessable
ccel-20200229_def.xml Edgar Link unprocessable
ccel-20200229_lab.xml Edgar Link unprocessable
ccel-20200229_pre.xml Edgar Link unprocessable
d900507d10q.htm Edgar Link pending
d900507dex311.htm Edgar Link pending
d900507dex312.htm Edgar Link pending
d900507dex313.htm Edgar Link pending
d900507dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending